Recent events
Recent events tied to this brand in public sources.
Back to profile51 entries · Page 1 of 3
2026
Novartis signs $7.8 billion mRNA deal with Abogen
Pharmaceutical company Novartis has signed a deal valued at $7.8 billion with Chinese company Abogen covering mRNA technology, as reported by IAM Patent.
2026
Novartis strikes up to $7.8 billion mRNA deal with China's Abogen
Novartis struck a deal with China-based Abogen worth up to $7.8 billion centered on mRNA, as reported on 2026-10-02.
2026
Novartis signs licensing agreement with Abogen Biosciences worth up to $7.8 billion
Swiss pharmaceutical company Novartis has entered a licensing agreement with China-based Abogen Biosciences worth up to $7.8 billion. Novartis will pay $575 million upfront for global rights to Abogen's lead asset, an early-stage experimental messenger RNA therapy for autoimmune disease, with an additional $7.2 billion in milestone payments, plus an exclusive option to license Abogen's assets developed on its RNA platform. Abogen announced the deal in a statement on Friday.
2026
Novartis recalls Diovan valsartan batch over dissolution specification failure
Novartis recalled a specific batch of its Diovan (valsartan) blood pressure drug after it failed to meet dissolution specifications, potentially reducing effectiveness. The FDA classified the notice as a Class II recall, warning of possible temporary or medically reversible adverse health consequences. The affected batch, marked AV5913C, consists of 90-count 160-mg tablets expiring June 2027, manufactured by Pantheon Manufacturing Services in Greenville, North Carolina and distributed nationwide in the US.
2022
FDA approves Novartis’ Locametz imaging agent
The FDA also approved Locametz, an imaging agent that can identify lesions in adult patients using a PET scan to help identify patients who may be eligible for targeted treatment with Pluvicto.
2022
Novartis acquires Gyroscope Therapeutics
Gyroscope Therapeutics was sold to Novartis for up to $1.5 billion, including an $800 million upfront cash payment and up to $700 million in milestone payments.
2022
Covis enters exclusive Canadian distribution agreement with Novartis
Covis entered an exclusive promotion and distribution agreement with Novartis Pharmaceuticals Canada to promote and distribute Seebri Breezhaler and Ultibro Breezhaler in Canada.
2021
BeiGene and Novartis expand their collaboration
BeiGene announced an agreement with Novartis to jointly develop, manufacture and commercialize BeiGene’s investigational TIGIT inhibitor ociperlimab in North America, Europe and Japan. The agreement also gives BeiGene rights to market and sell five approved Novartis oncology medicines in specified areas of China.
2021
IFM Due and Novartis extend collaboration agreement
IFM Therapeutics announced that its subsidiary IFM Due extended its collaboration and exclusive option agreement with Novartis to develop immunotherapies targeting the cGAS-STING pathway.
2021
Novartis launches Meet The PROS initiative
Novartis announced the launch of Meet The PROS, an initiative to raise awareness and provide educational resources about PIK3CA-Related Overgrowth Spectrum. The initiative includes a comic book, conversation guides, fact sheets and other resources, created with advocates, caregivers and patients.
2021
OcuMension agrees to acquire two ophthalmic drug businesses in mainland China from Novartis
OcuMension Therapeutics announced that it had entered into an agreement with Novartis to acquire all equity interests in two ophthalmic drugs in mainland China and obtain the corresponding manufacturing technology transfer. The transaction was announced, not reported as completed.
2021
Novartis partnered with Florida A&M University
Florida A&M University will benefit from a 10-year partnership with Novartis. The program is described as working toward eliminating disparities affecting minority groups in U.S. healthcare, especially in clinical trials; participating institutions will receive funding for education and research, and Novartis will mentor students.
2021
Novartis announces planned 10-year health equity collaboration
Novartis and the Novartis US Foundation announced a planned 10-year collaboration with Coursera, the National Medical Association, Thurgood Marshall College Fund, Morehouse School of Medicine, and 26 additional historically Black colleges, universities, and medical schools. The collaboration is intended to co-create programs addressing disparities in health outcomes and diversity in research and development.
2021
Novartis and HPE announce digital collaboration
Novartis announced a collaboration with Hewlett Packard Enterprise to accelerate its use of data and digital technologies. The initial effort aims to develop a dengue disease-surveillance solution, first focusing on India.
2021
FDA approves Cosentyx for pediatric plaque psoriasis
The U.S. Food and Drug Administration approved Novartis' Cosentyx for moderate to severe plaque psoriasis in pediatric patients aged six and older who are candidates for systemic therapy or phototherapy.
2021
Novartis reports 2020 financial results
Novartis released its 2020 financial results on January 26. The report showed net sales up 3% to $48.7 billion and core operating income up 13% to $15.4 billion.
2021
BeiGene and Novartis announce tislelizumab collaboration
BeiGene and Novartis announced a collaboration and license agreement to develop and commercialize BeiGene's tislelizumab in specified markets. Novartis will handle regulatory submissions after a transition period and commercialization after regulatory approval in those licensed countries.
2021
Novartis signs tislelizumab in-licensing agreement with BeiGene
Novartis signed an agreement to in-license tislelizumab from BeiGene, securing development and commercialization rights in specified markets outside China. BeiGene retains rights in China and other countries; the transaction remains subject to the applicable waiting period.
2020
Cadent Therapeutics agrees to be acquired by Novartis
Cadent Therapeutics entered into an agreement to be acquired by Novartis in a deal worth up to $770 million.
2020
RetinAI and Novartis announce ophthalmology collaboration
RetinAI Medical AG announced a multi-year collaboration with Novartis Pharma AG to use RetinAI's IT solutions and AI tools for multiple ophthalmology and digital-health projects. The first project will support an international clinical study involving more than 500 patients in European countries and Canada.